Johnson DE

References (5)

Title : An update on potential pharmacotherapies for cognitive impairment in bipolar disorder - Johnson_2023_Expert.Opin.Pharmacother__1
Author(s) : Johnson DE , McIntyre RS , Mansur RB , Rosenblat JD
Ref : Expert Opin Pharmacother , :1 , 2023
Abstract : INTRODUCTION: Cognitive impairment is a core feature of bipolar disorder (BD) that impedes recovery by preventing the return to optimal socio-occupational functioning and reducing quality of life. Presently, there are no efficacious treatments for cognitive impairment in BD, but many pharmacological interventions are being considered as they have the potential to target the underlying pathophysiology of the disorder. AREAS COVERED: This review summarizes the available evidence for pharmacological interventions for cognitive impairment in bipolar disorder. We searched PubMed, MedLine, and PsycInfo from inception to December 1(st,) 2022. Traditional treatments, such as lithium, anticonvulsants (lamotrigine), antipsychotics (aripiprazole, asenapine, cariprazine, lurasidone, and olanzapine), antidepressants (vortioxetine, fluoxetine, and tianeptine) and psychostimulants (modafinil), and emerging interventions, such as acetylcholinesterase inhibitors (galantamine and donepezil), dopamine agonists (pramipexole), erythropoietin, glucocorticoid receptor antagonists (mifepristone), immune modulators (infliximab, minocycline and doxycycline), ketamine, metabolic agents (insulin, metformin, and liraglutide), probiotic supplements, and Withania somnifera are discussed. EXPERT OPINION: The investigation of interventions for cognitive impairment in BD is a relatively under-researched area. In the past, methodological pitfalls in BD cognition trials have also been a critical limiting factor. Expanding on the existing literature and identifying novel pharmacological and non-pharmacological treatments for cognitive impairment in BD should be a priority.
ESTHER : Johnson_2023_Expert.Opin.Pharmacother__1
PubMedSearch : Johnson_2023_Expert.Opin.Pharmacother__1
PubMedID: 36946229

Title : A novel series of [3.2.1] azabicyclic biaryl ethers as alpha3beta4 and alpha6\/4beta4 nicotinic receptor agonists - Lowe_2010_Bioorg.Med.Chem.Lett_20_4749
Author(s) : Lowe JA, 3rd , DeNinno SL , Coe JW , Zhang L , Mente S , Hurst RS , Mather RJ , Ward KM , Shrikhande A , Rollema H , Johnson DE , Horner W , Gorczyca R , Tingley FD, 3rd , Kozak R , Majchrzak MJ , Tritto T , Sadlier J , Shaffer CL , Ellerbrock B , Osgood SM , MacDougall MC , McDowell LL
Ref : Bioorganic & Medicinal Chemistry Lett , 20 :4749 , 2010
Abstract : We report the synthesis of a series of [3.2.1]azabicyclic biaryl ethers as selective agonists of alpha3- and alpha6-containing nicotinic receptors. In particular, compound 17a from this series is a potent alpha3beta4 and alpha6/4beta4 receptor agonist in terms of both binding and functional activity. Compound 17a also shows potent in vivo activity in CNS-mediated animal models that are sensitive to antipsychotic drugs. Compound 17a may thus be a useful tool for studying the role of alpha3beta4 and alpha6/4beta4 nicotinic receptors in CNS pharmacology.
ESTHER : Lowe_2010_Bioorg.Med.Chem.Lett_20_4749
PubMedSearch : Lowe_2010_Bioorg.Med.Chem.Lett_20_4749
PubMedID: 20663668

Title : Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition - Rollema_2009_Biochem.Pharmacol_78(7)_813
Author(s) : Rollema H , Hajos M , Seymour PA , Kozak R , Majchrzak MJ , Guanowsky V , Horner WE , Chapin DS , Hoffmann WE , Johnson DE , McLean S , Freeman J , Williams KE
Ref : Biochemical Pharmacology , 78 :813 , 2009
Abstract : The pharmacological properties and pharmacokinetic profile of the alpha4beta2 nicotinic acetylcholine receptor (nAChR) partial agonist varenicline provide an advantageous combination of free brain levels and functional potencies at the target receptor that for a large part explain its efficacy as a smoking cessation aid. Since alpha4beta2 and other nAChR subtypes play important roles in mediating central processes that control reward, mood, cognition and attention, there is interest in examining the effects of selective nAChR ligands such as varenicline in preclinical animal models that assess these behaviors. Here we describe results from studies on varenicline's effects in animal models of addiction, depression, cognition and attention and discuss these in the context of recently published preclinical and preliminary clinical studies that collected data on varenicline's effects on mood, cognition and alcohol abuse disorder. Taken together, the preclinical and the limited clinical data show beneficial effects of varenicline, but further clinical studies are needed to evaluate whether the preclinical effects observed in animal models are translatable to the clinic.
ESTHER : Rollema_2009_Biochem.Pharmacol_78(7)_813
PubMedSearch : Rollema_2009_Biochem.Pharmacol_78(7)_813
PubMedID: 19501054

Title : The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine release - Johnson_2005_Eur.J.Pharmacol_506_209
Author(s) : Johnson DE , Nedza FM , Spracklin DK , Ward KM , Schmidt AW , Iredale PA , Godek DM , Rollema H
Ref : European Journal of Pharmacology , 506 :209 , 2005
Abstract : Olanzapine and clozapine produce robust increases in hippocampal acetylcholine release during acetylcholinesterase inhibition, while other antipsychotics, including thioridazine, have only small effects. Since thioridazine binds with similar high affinities to muscarinic receptors as olanzapine and clozapine, muscarinic autoreceptor blockade was ruled out as a primary mechanism [Neuropsychopharmacology 26 (2002) 583]. This study compared in vitro binding affinities and functional activities of olanzapine, clozapine, thioridazine, ziprasidone, risperidone, chlorpromazine and scopolamine at muscarinic M2 receptors with their in vivo potencies to increase acetylcholine release in the rat hippocampus. We found that scopolamine, olanzapine and clozapine, but also high doses of thioridazine and chlorpromazine, markedly increase acetylcholine release. The reduced in vivo potencies of thioridazine and chlorpromazine are consistent with their significantly weaker functional antagonist activity at human muscarinic M2 receptors, while thioridazine's reduced binding affinity for rat muscarinic M2 receptors and lower brain exposure, may further contribute to its weak in vivo potency compared to olanzapine. The excellent correlation between in vitro antagonist activities of antipsychotics at muscarinic M2 receptors and their in vivo potencies to increase acetylcholine release, suggests that olanzapine, clozapine, as well as thioridazine and chlorpromazine, increase acetylcholine release via blockade of terminal muscarinic M2 autoreceptors.
ESTHER : Johnson_2005_Eur.J.Pharmacol_506_209
PubMedSearch : Johnson_2005_Eur.J.Pharmacol_506_209
PubMedID: 15627430

Title : Early biochemical detection of delayed neurotoxicity resulting from developmental exposure to chloropyrifos - Johnson_1998_Brain.Res.Bull_45_143
Author(s) : Johnson DE , Seidler FJ , Slotkin TA
Ref : Brain Research Bulletin , 45 :143 , 1998
Abstract : Developing animals are more sensitive than adults to the delayed neurotoxicity caused by chlorpyrifos exposure. In developing rat brain, chlorpyrifos doses that cause no discernible systemic toxicity and only a minor degree of cholinesterase inhibition, nevertheless evoke alterations in cell function and number that appear after several days' delay. In the current study, neonatal rats were exposed to subtoxic doses of chlorpyrifos (no weight loss or mortality) on either postnatal days 1-4, or postnatal days 11-14, and the effects on cellular RNA levels were determined in two brain regions that are targeted for delayed neurotoxicity-the brainstem and forebrain. In both regions, chlorpyrifos exposure evoked significant alterations in RNA concentration and content, variables that are ordinarily very tightly controlled in the developing brain. The effects on RNA appeared well before the deficits in cell function and number and showed a regional selectivity similar to that of subsequent, delayed neurotoxicity. Deficits in RNA were more prominent in the brainstem, an early-developing brain region, than in the forebrain, which develops later. These results suggest that chlorpyrifos can elicit delayed developmental neurotoxicity by targeting the pivotal macromolecules that control cell differentiation in a critical postmitotic period. The lower threshold for these cellular effects compared to that for systemic toxicity indicates that the developing brain is a selective target for chlorpyrifos, effects that should be considered in assessing safety thresholds.
ESTHER : Johnson_1998_Brain.Res.Bull_45_143
PubMedSearch : Johnson_1998_Brain.Res.Bull_45_143
PubMedID: 9443830